Copyright Reports & Markets. All rights reserved.

Global and United States Parkinson’s Disease Therapeutics Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Parkinson’s Disease Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Oral
    • 1.2.3 Transdermal
    • 1.2.4 Subcutaneous
    • 1.2.5 Intestinal Infusion
  • 1.3 Market by Application
    • 1.3.1 Global Parkinson’s Disease Therapeutics Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospitals
    • 1.3.3 Clinics
    • 1.3.4 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Parkinson’s Disease Therapeutics Market Perspective (2015-2026)
  • 2.2 Global Parkinson’s Disease Therapeutics Growth Trends by Regions
    • 2.2.1 Parkinson’s Disease Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Parkinson’s Disease Therapeutics Historic Market Share by Regions (2015-2020)
    • 2.2.3 Parkinson’s Disease Therapeutics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Parkinson’s Disease Therapeutics Players by Market Size
    • 3.1.1 Global Top Parkinson’s Disease Therapeutics Players by Revenue (2015-2020)
    • 3.1.2 Global Parkinson’s Disease Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.2 Global Parkinson’s Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Parkinson’s Disease Therapeutics Revenue
  • 3.4 Global Parkinson’s Disease Therapeutics Market Concentration Ratio
    • 3.4.1 Global Parkinson’s Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Parkinson’s Disease Therapeutics Revenue in 2019
  • 3.5 Key Players Parkinson’s Disease Therapeutics Area Served
  • 3.6 Key Players Parkinson’s Disease Therapeutics Product Solution and Service
  • 3.7 Date of Enter into Parkinson’s Disease Therapeutics Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Parkinson’s Disease Therapeutics Breakdown Data by Type (2015-2026)

  • 4.1 Global Parkinson’s Disease Therapeutics Historic Market Size by Type (2015-2020)
  • 4.2 Global Parkinson’s Disease Therapeutics Forecasted Market Size by Type (2021-2026)

5 Parkinson’s Disease Therapeutics Breakdown Data by Application (2015-2026)

  • 5.1 Global Parkinson’s Disease Therapeutics Historic Market Size by Application (2015-2020)
  • 5.2 Global Parkinson’s Disease Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Parkinson’s Disease Therapeutics Market Size (2015-2026)
  • 6.2 North America Parkinson’s Disease Therapeutics Market Size by Type (2015-2020)
  • 6.3 North America Parkinson’s Disease Therapeutics Market Size by Application (2015-2020)
  • 6.4 North America Parkinson’s Disease Therapeutics Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Parkinson’s Disease Therapeutics Market Size (2015-2026)
  • 7.2 Europe Parkinson’s Disease Therapeutics Market Size by Type (2015-2020)
  • 7.3 Europe Parkinson’s Disease Therapeutics Market Size by Application (2015-2020)
  • 7.4 Europe Parkinson’s Disease Therapeutics Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Parkinson’s Disease Therapeutics Market Size (2015-2026)
  • 8.2 China Parkinson’s Disease Therapeutics Market Size by Type (2015-2020)
  • 8.3 China Parkinson’s Disease Therapeutics Market Size by Application (2015-2020)
  • 8.4 China Parkinson’s Disease Therapeutics Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Parkinson’s Disease Therapeutics Market Size (2015-2026)
  • 9.2 Japan Parkinson’s Disease Therapeutics Market Size by Type (2015-2020)
  • 9.3 Japan Parkinson’s Disease Therapeutics Market Size by Application (2015-2020)
  • 9.4 Japan Parkinson’s Disease Therapeutics Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Parkinson’s Disease Therapeutics Market Size (2015-2026)
  • 10.2 Southeast Asia Parkinson’s Disease Therapeutics Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Parkinson’s Disease Therapeutics Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Parkinson’s Disease Therapeutics Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Abbvie
    • 11.1.1 Abbvie Company Details
    • 11.1.2 Abbvie Business Overview
    • 11.1.3 Abbvie Parkinson’s Disease Therapeutics Introduction
    • 11.1.4 Abbvie Revenue in Parkinson’s Disease Therapeutics Business (2015-2020))
    • 11.1.5 Abbvie Recent Development
  • 11.2 Biogen
    • 11.2.1 Biogen Company Details
    • 11.2.2 Biogen Business Overview
    • 11.2.3 Biogen Parkinson’s Disease Therapeutics Introduction
    • 11.2.4 Biogen Revenue in Parkinson’s Disease Therapeutics Business (2015-2020)
    • 11.2.5 Biogen Recent Development
  • 11.3 Boehringer Ingelheim GmbH
    • 11.3.1 Boehringer Ingelheim GmbH Company Details
    • 11.3.2 Boehringer Ingelheim GmbH Business Overview
    • 11.3.3 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Introduction
    • 11.3.4 Boehringer Ingelheim GmbH Revenue in Parkinson’s Disease Therapeutics Business (2015-2020)
    • 11.3.5 Boehringer Ingelheim GmbH Recent Development
  • 11.4 F. Hoffman-La Roche
    • 11.4.1 F. Hoffman-La Roche Company Details
    • 11.4.2 F. Hoffman-La Roche Business Overview
    • 11.4.3 F. Hoffman-La Roche Parkinson’s Disease Therapeutics Introduction
    • 11.4.4 F. Hoffman-La Roche Revenue in Parkinson’s Disease Therapeutics Business (2015-2020)
    • 11.4.5 F. Hoffman-La Roche Recent Development
  • 11.5 GlaxoSmithKline
    • 11.5.1 GlaxoSmithKline Company Details
    • 11.5.2 GlaxoSmithKline Business Overview
    • 11.5.3 GlaxoSmithKline Parkinson’s Disease Therapeutics Introduction
    • 11.5.4 GlaxoSmithKline Revenue in Parkinson’s Disease Therapeutics Business (2015-2020)
    • 11.5.5 GlaxoSmithKline Recent Development
  • 11.6 H. Lundbeck A/S
    • 11.6.1 H. Lundbeck A/S Company Details
    • 11.6.2 H. Lundbeck A/S Business Overview
    • 11.6.3 H. Lundbeck A/S Parkinson’s Disease Therapeutics Introduction
    • 11.6.4 H. Lundbeck A/S Revenue in Parkinson’s Disease Therapeutics Business (2015-2020)
    • 11.6.5 H. Lundbeck A/S Recent Development
  • 11.7 Impax Labs
    • 11.7.1 Impax Labs Company Details
    • 11.7.2 Impax Labs Business Overview
    • 11.7.3 Impax Labs Parkinson’s Disease Therapeutics Introduction
    • 11.7.4 Impax Labs Revenue in Parkinson’s Disease Therapeutics Business (2015-2020)
    • 11.7.5 Impax Labs Recent Development
  • 11.8 Newron Pharmaceuticals SpA
    • 11.8.1 Newron Pharmaceuticals SpA Company Details
    • 11.8.2 Newron Pharmaceuticals SpA Business Overview
    • 11.8.3 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Introduction
    • 11.8.4 Newron Pharmaceuticals SpA Revenue in Parkinson’s Disease Therapeutics Business (2015-2020)
    • 11.8.5 Newron Pharmaceuticals SpA Recent Development
  • 11.9 Novartis AG
    • 11.9.1 Novartis AG Company Details
    • 11.9.2 Novartis AG Business Overview
    • 11.9.3 Novartis AG Parkinson’s Disease Therapeutics Introduction
    • 11.9.4 Novartis AG Revenue in Parkinson’s Disease Therapeutics Business (2015-2020)
    • 11.9.5 Novartis AG Recent Development
  • 11.10 Orion Corporation
    • 11.10.1 Orion Corporation Company Details
    • 11.10.2 Orion Corporation Business Overview
    • 11.10.3 Orion Corporation Parkinson’s Disease Therapeutics Introduction
    • 11.10.4 Orion Corporation Revenue in Parkinson’s Disease Therapeutics Business (2015-2020)
    • 11.10.5 Orion Corporation Recent Development
  • 11.11 Teva Pharmaceutical Industries Ltd.
    • 10.11.1 Teva Pharmaceutical Industries Ltd. Company Details
    • 10.11.2 Teva Pharmaceutical Industries Ltd. Business Overview
    • 10.11.3 Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Introduction
    • 10.11.4 Teva Pharmaceutical Industries Ltd. Revenue in Parkinson’s Disease Therapeutics Business (2015-2020)
    • 10.11.5 Teva Pharmaceutical Industries Ltd. Recent Development
  • 11.12 UCB S.A.
    • 10.12.1 UCB S.A. Company Details
    • 10.12.2 UCB S.A. Business Overview
    • 10.12.3 UCB S.A. Parkinson’s Disease Therapeutics Introduction
    • 10.12.4 UCB S.A. Revenue in Parkinson’s Disease Therapeutics Business (2015-2020)
    • 10.12.5 UCB S.A. Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Parkinson’s Disease Therapeutics Scope and Market Size
    Parkinson’s Disease Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Parkinson’s Disease Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Oral
    Transdermal
    Subcutaneous
    Intestinal Infusion

    Market segment by Application, split into
    Hospitals
    Clinics
    Others

    Based on regional and country-level analysis, the Parkinson’s Disease Therapeutics market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Parkinson’s Disease Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Abbvie
    Biogen
    Boehringer Ingelheim GmbH
    F. Hoffman-La Roche
    GlaxoSmithKline
    H. Lundbeck A/S
    Impax Labs
    Newron Pharmaceuticals SpA
    Novartis AG
    Orion Corporation
    Teva Pharmaceutical Industries Ltd.
    UCB S.A.

    Buy now